The European Society for Medical Oncology (ESMO) annual congress is one of the most important gatherings in the global oncology calendar. This year, the meeting will take place in Berlin from 17–21 October, uniting innovators, researchers, and leaders committed to advancing cancer care.
At Inizio, oncology is our largest therapeutic area for strategic and branded work. With over 30 years of experience, we bring unrivalled scientific expertise, advanced technology, and AI-driven insights to simplify complexity and unlock value across the patient journey.
In 2024 alone, we supported more than 140 oncology assets in early pre-commercialization and worked on 95% of the top 20 oncology products. These milestones reflect our commitment to delivering bespoke solutions that bridge scientific innovation with the realities of the patient journey.
Our experts will be attending ESMO 2025 in Berlin to connect with partners, share perspectives, and continue driving forward bold ideas in oncology. Whether it’s aligning strategy, enhancing engagement, or enabling smarter decisions, we work to ensure life-changing treatments reach the patients who need them most.
If you’d like to meet our team at ESMO, please get in touch.
Jump to a slide with the slide dots.
Inizio appoints Ryan Quigley as CEO to lead next phase of growth
We are delighted to announce the appointment of Ryan Quigley as Chief Executive Officer, effective 9 September 2025.
Read moreInizio Medical and Inizio Evoke named finalists at 2025 Fierce Pharma Marketing Awards
We’re proud to announce that our teams across Inizio Medical and Inizio Evoke have been named finalists in three categories.
Read moreInizio celebrates six finalist honors at the 2025 PM360 Trailblazer Awards
We have been named finalists in six prestigious categories at the 2025 PM360 Trailblazer Awards, which recognize excellence and innovation.
Read more